This article is more than 5 years old. Information may no longer be current.
Pharmaceutical company receives NIH grant to treat rare endocrine disorders
Click Here to Manage Email Alerts
Crinetics Pharmaceuticals, a company that focuses on therapeutics for endocrine disorders and related cancers, has received two new grants from the National Institute of Diabetes and Digestive and Kidney Diseases of the NIH, according to a company press release.
The company reports it will use the grants to develop its nonpeptide, oral somatostatin agonists for congenital hyperinsulinemia in addition to novel small-molecule drugs for Cushing’s disease.
“We are delighted with the NIH’s continuing support of our programs to develop new drugs for patients with rare endocrine disorders,” Stephen Betz, PhD, founder and vice president of biology at Crinetics. “These awards will enable us to advance our efforts in both hyperinsulinemia and Cushing’s disease, expanding our pipeline to include these diseases with significant unmet medical needs, and bring these treatments to the patients who need them.”
Combined, the grants could total $2.4 million.